Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||TET2 R1896M|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TET2 mutant||acute myeloid leukemia||not applicable||N/A||Clinical Study||Prognostic||In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606).||24524305 25412851 24994606|
|TET2 mutant||angioimmunoblastic T-cell lymphoma||not applicable||N/A||Guideline||Diagnostic||TET2 mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).||detail...|
|TET2 mutant||acute myeloid leukemia||predicted - sensitive||Azacitidine||Phase I||Actionable||In a retrospective analysis, presence of a TET2 mutation correlated with higher overall response rate (ORR) in patients with myelodysplastic syndrome and acute myeloid leukemia following treatment with Vidaza (azacitidine), with an ORR of 85% (11/3) in TET2-mutated patients, compared to 47% (34/47) in patients with wild-type TET2, but did not correlate with overall survival (PMID: 21494260).||21494260|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|